Now, the work has been awarded the prestigious Breakthrough Prize at the "Oscars of Science." Today, Jean Bennett, MD, PHD, and Albert Maguire, MD, both emeritus professors of Ophthalmology in the ...

Merck will acquire Terns for $53 per share in cash, amounting to an equity value of about $6.7 billion. This is the third multibillion-dollar acquisition for Merck over the past year as it looks to ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

After generating interest from the likes of Pfizer and GSK, Quotient Therapeutics’ somatic genomics platform has attracted another Big Pharma suitor in Merck & Co. Looking to devise new drug targets ...

Merck & Co. is rounding out its March deal flurry with an antibody discovery pact that could be worth as much as $838 million. The New Jersey pharma is tapping Infinimmune to hunt for antibodies for ...

Merck & Co. agreed to buy Terns Pharmaceuticals Inc. for $6.7 billion, giving the multinational company access to a promising new leukemia treatment as it faces the patent expiration of its ...

March 24 (Reuters) - Pharmaceutical company Merck (MRK.N), opens new tab is nearing a roughly $6 billion ‌all-cash deal to acquire biotech firm Terns Pharma (TERN.O), opens new tab, the Financial ...

Merck & Co. (MRK) is close to an approximately $6 billion all-cash deal to buy U.S. biotech firm Terns Pharmaceuticals (TERN) as it seeks to boost its drug pipeline ahead of cancer treatment ...

Some investors are questioning the premium Merck (MRK) is paying in its $6.7 billion acquisition of Tern Pharmaceuticals (TERN), according to an RBC analyst. Merck agreed to pay $53 a share for Terns ...

Merck is picking up a big new piece for its cancer drug pipeline with a $6.7 billion deal to acquire Terns Pharmaceuticals, a company whose lead program could rival a blockbuster product from Novartis ...

Transaction terms include a 31% premium to 60-day and 42% to 90-day VWAP, with an expected ~$5.8B charge reflected in Q2 and FY 2026 results. Targeting the ABL myristoyl pocket differentiates TERN-701 ...

Merck to pay a 6% premium to buy the outstanding shares of Terns Pharmaceuticals, which is developing an oral treatment for leukemia Merck to spend $6.7 billion to buy Terns Pharmaceuticals, which is ...